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The NFκB-signaling pathway regulates cell proliferation and 
inflammation. Activation of the pathway is implicated in the etiol-
ogy of colorectal cancer (CRC). NSAIDs may reduce CRC risk 
partially through a nuclear factor-kappa B (NFκB)-dependent 
pathway. In this study, we investigated associations between 
34 NFκB1 and 8 IκBKβ tagSNPs and CRC risk and exam-
ined interactions with non-steroidal anti-inflammatory drug 
(NSAID) use. Using conditional logistic regression, we investi-
gated these associations among 1584 incident CRC cases and 
2516 sibling controls from the Colon Cancer Family Registry. 
Three IκBKβ SNPs were associated with a statistically significant 
lower colorectal or colon cancer risk: rs9694958 (A>G intron 5) 
(colorectal: ORhzv  =  0.26(0.07–0.99), Ptrend  =  0.048, Padj  =  0.25), 
rs10958713 (A>C intron 19) (colon: ORhzv  =  0.62(0.42–0.92), 
Ptrend = 0.005, Padj = 0.03) and rs5029748 (C>A intron 2) (colon: 
ORhet = 0.72(0.56–0.91), Ptrend = 0.01, Padj = 0.08). We replicated 
trends associated with NFκB1 and IκBKβ variants identified in 
a previous study (rs4648110 (T>A intron 22), rs13117745 (G>A 
intron 5) and rs3747811 (T>A intron 1)). IκBKβ’s rs6474387 
(C>T intron 20) and rs11986055 (A>C intron 2) showed sub-
stantially lower colon cancer risk among current NSAID users 
(Pinteraction  =  0.01 and Pinteraction  =  0.045, respectively), whereas 
NFκB1’s rs230490 (G>A 5ʹ (outside UTR)) and rs997476 (C>A 3ʹ 
(outside UTR)) showed higher CRC risk among current NSAID 
users (Pinteraction = 0.01 and Pinteraction = 0.03, respectively). These 
findings suggest that variants in NFκB1 and IκBKβ are associ-
ated with CRC risk and NSAIDs may function partially through 
an NFκB-dependent pathway. The SNPs identified here should 
be considered for future functional studies and may be useful in 
designing a pharmacogenetic approach to preventive NSAID use.
Introduction
Results from epidemiologic and experimental studies have pointed 
to chronic inflammation as an important cause of colorectal cancer 
(CRC ) (1–3). The exact mechanism(s) through which inflammation 
contributes to CRC etiology and the extent to which inflammation 
differentially impacts colon and rectal cancer etiology are still being 
investigated (4); however, growing evidence suggests that one rele-
vant mechanism is the nuclear factor-kappa B (NFκB)-signaling 
pathway (5). The NFκB signaling pathway regulates cell prolifer-
ation, apoptosis and inflammatory responses, through activation of an 
ubiquitous transcription factor, NFκB (5). Constitutive activation of 
NFκB has been observed in 40% of CRC tissues and in 67% of CRC 
cell lines (6).
NFκB is found as a homo- or heterodimeric complex (7). The most 
commonly studied NFκB complex is the RelA:p50 heterodimer (8). In 
the cytoplasm, RelA:p50 is normally bound to an inhibitory protein, 
IκBα, rendering the transcription factor inactive. In response to a wide 
array of stimuli, including proinflammatory cytokines and chemoki-
nase, the IκB kinase (IKK) complex phosphorylates IκBα, causing 
degradation of IκBα and activation of NFκB. Once activated, NFκB 
translocates to the nucleus where it binds to the promoter region of 
its target genes (5,7). The IKK complex is composed of two catalytic 
subunits, IKKα and IKKβ, with IKKβ required for activation of the 
RelA:p50 dimer (5). The NFκB1 gene encodes p50 and the IκBKβ 
gene encodes IKKβ. Initial studies have suggested that genetic vari-
ability in NFκB1 and IκBKβ is associated with CRC risk (9,10) and 
that genetic variability in IκBKβ is associated with CRC survival (11).
Several studies, including randomized trials, have shown that the 
regular use of non-steroidal anti-inflammatory drugs (NSAIDs) is 
associated with decreased CRC incidence and mortality (12–14). 
Reduction in inflammation by NSAIDs is generally attributed to 
inhibition of prostaglandin synthesis (3,15), but there is evidence 
that several NSAIDs, including aspirin, also inhibit NFκB activation 
(16,17) and induce CRC cell apoptosis through an NFκB-dependent 
mechanism (18–20). Thus, it is biologically plausible that variation in 
NFκB signaling pathway genes, including NFκB1 and IκBKβ, mod-
ify the inverse association between NSAID use and CRC risk.
We have shown previously that genetic variability in prostaglandin 
synthesis and inflammation can influence risk of CRC (21–26). The 
purpose of this study was to investigate the association between gen-
etic variability in NFκB1 and IκBKβ and risk of CRC and to investi-
gate the interaction between genetic variability in NFκB1 and IκBKβ 
and NSAIDs on the risk of CRC using a case–unaffected sibling con-
trol design in the Colon Cancer Family Registry (CCFR).
Materials and methods
Study population and questionnaire data
The study population has been described previously (27). Briefly, CRC cases 
were recruited for the CCFR from six registry centers. The CCFR cases were 
probands and affected relatives diagnosed with primary invasive CRC from 
1998 to 2002 who were interviewed within 5 years of diagnosis. Controls were 
siblings without a CRC diagnosis at the time of ascertainment. Although eligi-
bility requirements varied slightly, registry centers typically required partici-
pants to be between the ages of 20 and 74 (27).
Standard questionnaires were used to collect epidemiologic data from CCFR 
study participants regarding demographic characteristics, medical history, 
NSAID use, family history of cancer, smoking history, diet, physical activity, 
height and weight. Regular NSAID use was defined as use two or more times 
per week for at least 1  month. Current NSAID use was defined as regular 
use in the 2 years prior to study enrollment. Blood and tissue samples were 
collected according to standardized procedures. Individuals were excluded 
from this study if the case did not have at least one matched unaffected sibling 
as a control and if an individual’s sex determined by genotyping did not 
match reported sex on the questionnaire. Only self-reported Caucasian study 
participants, ascertained through population-based recruitment, were included 
in this analyses (sample sizes among other racial/ethnic groups and clinic-
based populations were too small to assess associations).
Informed consent was obtained from all participants. The Institutional 
Review Boards at each CCFR site approved the study.
Abbreviations: BMI, body mass index; CCFR, Colon Cancer Family 
Registry; CI, confidence interval; CRC, colorectal cancer; FDR, false dis-
covery rate; IKK, IκB kinase; LD, linkage disequilibrium; MAF, minor 
allele frequency; NFκB, nuclear factor-kappa B; NSAID, non-steroidal anti-
inflammatory drugs; OR, odds ratio; UTR, untranslated region.
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SNP selection
A list of SNPs examined in this study can be found in Supplementary Table 1, 
available at Carcinogenesis Online. The procedure for tagSNP selection for 
the parent study has been published previously (28). Briefly, tagSNPs for 
NFκB1 (n = 42) and IκBKβ (n = 10) were selected using Haploview Tagger 
(29) with the following criteria: minor allele frequency (MAF) >5%, pairwise 
r2 of >0.95 and distance from closest SNP of >60 base pairs (bp). The 5′ and 
3′ untranslated regions (UTR) for each gene were extended to include the most 
up- or downstream SNP within the linkage disequilibrium (LD) block (~10 kb 
upstream and 5kb downstream). In regions of no or low LD, SNPs with a 
MAF >5% at a density of ~ 1 per kb were selected from either HapMap (29) 
or dbSNP (30). The tag SNPs included two non-synonymous SNPs each from 
NFκB1 and IκBKβ.
Genotyping and quality control
DNA was extracted from peripheral blood leukocytes, and genotyping was 
performed at Translational Genomics Institute (TGen, Phoenix, AZ). SNPs 
were genotyped on the Illumina 1536 GoldenGate platform (31). Quality 
control checks were based on Illumina metrics, as described previously (32). 
Three SNPs (rs4648099, rs6813322 and rs6474387) that were not success-
fully genotyped on the Illumina platform were genotyped using Sequenom’s 
iPLEX Gold (Sequenom, Inc). Five percent of the samples were re-genotyped 
to assess reliability. Concordance among duplicates was >99.8% for all SNPs. 
SNPs were excluded if the Hardy–Weinberg equilibrium P value among 
controls was <0.0001 or the call rate was <85%. The two non-synonymous 
SNPs from IκBKβ, rs2272763 and rs17875749, were excluded from analy-
sis because they were not encountered in our population. From NFκB1, eight 
SNPs were excluded: two SNPs were not in Hardy–Weinberg equilibrium 
(including one non-synonymous SNP, rs4648099), and six SNPs were in LD 
(r2 > 0.90) with another SNP with nearly identical genotype frequencies. After 
these exclusions, eight IκBKβ SNPs and 34 NFκB1 remained for analysis 
(Supplementary Table 1, available at Carcinogenesis Online).
Statistical analysis
Single SNP main effects. Conditional logistic regression was used to estimate 
odds ratios (OR) and 95% confidence intervals (CI). A variable that indicated 
unique sibling kinships was used as the matching variable, and models were 
adjusted for age and sex. For each SNP, the risk of CRC was estimated using a 
codominant model, unless any cell had fewer than five individuals, in which 
case a dominant model was used. A global P value (two degrees of freedom 
for codominant models), determined using the likelihood ratio statistic, was 
used to test for differences between carriers of the variant allele and homo-
zygous carriers of the wild-type allele. A trend test was performed using the 
log-additive model to determine if there was a dose-dependent association 
with the variant allele.
Interaction analyses. Conditional logistic regression was used to investigate 
the interaction between SNPs and current NSAID use, as well as between SNPs 
of NFκB1 and IκBKβ. OR estimates and 95% CIs were calculated for each 
combination of genotype(s) and/or NSAID use status (current or former/never). 
In this study population, current NSAID use was more strongly inversely asso-
ciated with CRC risk than other aspects of NSAID use and thus we chose it 
as the primary variable for interaction analysis. The reference groups were 
composed of individuals who were homozygous for the wild-type allele(s) and 
never/former users of NSAIDs. Because use of NSAIDs may be associated 
with other known risk factors for CRC, NSAID interactions were adjusted for 
smoking (continuous pack-years), body mass index (BMI) (continuous) and 
physical activity (four-level ordinal variable based on average MET hours) in 
addition to age (continuous) and sex. For SNP-SNP interactions, only SNPs 
independently associated with CRC risk (global P < 0.05) were combined with 
the other SNPs in this study to create composite genotypes. To avoid small cell 
counts, only the dominant model and composite genotypes that represented at 
least 5% of the population were examined. The likelihood ratio test compared 
models with and without the multiplicative interaction term(s) to determine 
if an interaction was statistically significant (Pinteraction). All tests of statistical 
significance used a two-sided P value and α = 0.05. Analyses were carried out 
using SAS v.9.3 (SAS Institute Inc, Cary, NC).
Multiple testing corrections. The correction method for multiple correlated 
tests developed by Conneely and Boehnke was used for main effects ana-
lyses (33). P values adjusted for correlated tests are referred to as Pact, with 
Pact < 0.05 considered statistically significant. All P value adjustments were 
conducted in R (version 2.14.1). The more conservative family wise error 
rate methods of multiple testing corrections often prevent the detection of 
true associations. Thus, the false discovery rate (FDR) control method devel-
oped by Benjamini and Hochberg (11,34,35), was used to identify SNPs note-
worthy at the 25% FDR levels for both main effect and NSAID interaction 
analyses. Tables II andIII include only SNPs that had a significant global P, 
Ptrend or Pinteraction value or were noteworthy by FDR.
Replication of previous study results
We used this study to attempt replication of the results of Curtin et al. (9). 
(the only other study to examine the association between genetic varia-
tion in these genes and colorectal cancer using a tagSNP method). Curtin 
et al. examined the association between individual or composite genotypes 
of NFκB1 and IκBKβ SNPs and colon or rectal cancer adjusted for age, 
sex, center and race under the additive, dominant and recessive models. In 
the replication analysis, only ORs and 95% CIs are presented for individual 
genotypes or composite genotypes, as these were the parameters reported by 
Curtin et al. (9).
Results
Characteristics of the study sample are presented in Table I. There 
were no obvious differences between cases and unaffected sibling 
controls by age, regular NSAID use, pack-years of cigarette smoking 
and physical activity or BMI. Cases were more likely than controls 
to be male.
SNP risk estimates
Among the tagSNPs in IκBKβ, one SNP was associated with lower 
CRC risk, before corrections for multiple testing (Table II). Individuals 
with the homozygous variant genotype of rs9694958 (A>G intron 
5) had an almost 4-fold lower CRC risk than individuals homozygous 
for the wild-type allele (ORhzv  =  0.26, 95% CI 0.07–0.99, global 
P = 0.048, Pact = 0.25).
After stratifying by tumor subsite, two SNPs in IκBKβ were stat-
istically significantly associated with lower colon cancer risk (Table 
II). Carriers of rs10958713 (A>C intron 19) had 1.4- to 1.6-fold lower 
colon cancer risk (ORhet = 0.73, 95% CI 0.57–0.92; ORhzv = 0.62, 95% 
CI 0.42–0.92, global P = 0.02, Pact = 0.09). The variant allele showed 
a dose-dependent association, which remained statistically significant 
after correction for multiple testing (Ptrend = 0.005, Pact = 0.03). Carriers 
of rs5029748 (C>A intron 2) had a 1.4-fold lower colon cancer risk 
Table I. Selected characteristics of colorectal cancer cases and unaffected 
sibling controls, the Colon Cancer Family Registry, 1998–2002
Characteristic Cases (N = 1584)a Unaffected sibling 
controls (N = 2516)a
n (%) or mean ± SD n (%) or mean ± SD
Age (years) ± SD 53.5 ± 10.8 54.0 ± 11.7
Male 810 (51.1) 1126 (44.8)
Center site
 Ontario 296 (18.7) 491 (19.5)
 Los Angeles 319 (20.1) 444 (17.7)
 Australia 317 (20.0) 554 (22.0)
 Hawaii 6 (0.4) 7 (0.3)
 Mayo 266 (16.8) 502 (20.0)
 Seattle 380 (24.0) 518 (20.6)
Tumor site
 Proximal 526 (33.2) —
 Distal 460 (29.0) —
 Rectal 523 (33.0) —
Regular NSAID useb
 Never/former 1234 (78.3) 1916 (76.9)
 Current 343 (21.8) 577 (23.1)
Physical activity
 Inactive 375 (23.7) 585 (23.3)
 Less active 424 (26.8) 679 (27.0)
 Active 374 (23.6) 564 (22.4)
 Very active 338 (21.3) 548 (21.8)
BMI ± SD 27.4 ± 6.0 26.8 ± 5.5
Cigarette smoking  
(pack-years) ± SD
12.9 ± 19.5 11.7 ± 19.3
aNumbers may not add to total because of missing data.
bRegular use defined as at least two pills per week for at least one month. This 
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(ORhet = 0.72, 95% CI 0.56–0.91; ORhzv = 0.72, 95% CI 0.44–1.18, 
global P  =  0.02, Pact=0.11). The variant allele showed a dose-
dependent association (Ptrend = 0.01, Pact = 0.08). The rs5029748 and 
rs10958713 variants were noteworthy at the 25% FDR level for asso-
ciations with colon cancer risk; thus the chance that these SNPs are 
truly associated with risk is ~75%.
No tagSNP in IκBKβ had a statistically significant association with 
rectal cancer risk. The complete analysis of the associations between 
SNPs in IκBKβ and colorectal cancer is presented in Supplementary 
Table 2, available at Carcinogenesis Online.
No SNP in NFκB1 was statistically significantly associated with 
risk of colorectal, colon or rectal cancer and no SNP was notewor-
thy by FDR. Individuals carrying one copy of the single non-syn-
onymous SNP in NFκB1, M507V (rs4648072), showed a reduced, 
but statistically non-significant, risk of CRC (ORhet = 0.62, 95% CI 
0.24–1.60, global P = 0.50). The rs10489113 variant allele (A>G 
3′ outside UTR) had a dose-dependent association when the analy-
sis was restricted to colon cancer, prior to correction for multiple 
correlated tests (Ptrend  =  0.04, Pact  =  0.48) (Table II). Individuals 
homozygous for this variant allele had an ~2-fold lower risk of 
colon cancer (ORhzv  =  0.53, 95% CI 0.29–0.97). The complete 
analysis of the associations between SNPs in NFκB1 and colorec-
tal cancer risk is presented in Supplementary Table 3, available at 
Carcinogenesis Online.
SNP-SNP interactions
We did not observe any statistically significant interactions between 
SNPs (data not shown). Of the three SNPs independently associ-
ated with CRC and, therefore, potentially eligible for this analysis, 
rs9694958 was not included because individuals with the risk-associ-
ated genotype represented <5% of the population.
NSAID interactions
Current NSAID use was associated with a statistically non-significant 
reduced CRC risk in the study population (OR = 0.87, P = 0.13). Two 
SNPs in IκBKβ, rs6474387 (C>T intron 20) and rs11986055 (A>C 
intron 2), altered the association between NSAID use and colon cancer 
risk (Table III). Current NSAID users who carried the rs6474387 
variant allele had statistically significant lower risk of colon cancer 
(OR = 0.38, 95% CI 0.16–0.86), which was not observed in current 
NSAID users who did not carry the variant allele (Pinteraction = 0.01). 
The interaction between rs11986055 and NSAID use was similar 
(LD r2 between rs6474387 and rs11986055 was 0.50); only current 
NSAID users who carried the variant allele had lower colon cancer 
risk (OR = 0.47, 95% CI 0.17–1.13, Pinteraction = 0.045). FDR analysis 
identified the interactions for both rs6474387 and rs11986055 as 
noteworthy at the 25% level when the analysis was restricted to 
colon cancer. There were no statistically significant or noteworthy 
interactions between IκBKβ SNPs and NSAID use for rectal cancer.
For the non-synonymous SNP in NFκB1, M507V, there was no 
statistically significant interaction with NSAID use. Two other tag-
SNPs in NFκB1, rs230490 (G>A 5′ outside UTR) and rs997476 
(C>A 3′ outside UTR), were associated with a statistically signifi-
cantly altered association between NSAID use and CRC risk (Table 
III). Among individuals with the homozygous wild-type and hetero-
zygous genotypes of rs230490 current NSAID use was associated 
with lower CRC risk; however, among individuals with the homozy-
gous variant genotype current NSAID use resulted in a trend toward 
higher CRC risk (OR = 1.29, 95% CI 0.82–2.03, Pinteraction = 0.008). 
The interaction between rs230490 and NSAID use remained statis-
tically significant when the analysis was restricted to rectal cancer 
risk, but not for colon cancer risk. There was also a nominally sig-
nificant SNP-NSAID interaction for rs997476, with higher CRC risk 
Table III. Association between NSAID use and colorectal, colon or rectal cancer risk stratified by selected IκBKβ and NFκB1 SNP genotypesa,b
Genotype Colorectal Cancer Colon Cancer Rectal Cancer
Never or former  
NSAID use
Current NSAID use Never or former  
NSAID use
Current NSAID use Never or former 
NSAID use
Current NSAID use
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
IκBKβ
rs6474387 (C>T intron 20)
C/C 1.00 Ref. 0.91 (0.75–1.08) 1.00 Ref. 0.93 (0.72–1.18) 1.00 Ref. 0.80 (0.54–1.19)
C/T or T/Tc 1.00 (0.72–1.40) 0.56 (0.31–1.02) 1.11 (0.71–1.72) 0.38 (0.16–0.86) 1.10 (0.65–1.86) 0.84 (0.35–2.04)
Pinteraction = 0.10 Pinteraction = 0.01**
,c Pinteraction = 0.93
rs11986055 (A>C intron 2)
A/A 1.00 Ref. 0.90 (0.74–1.09) 1.00 Ref. 0.89 (0.70–1.14) 1.00 Ref. 0.81 (0.56–1.18)





A/A 1.00 Ref. 0.87 (0.72–1.05) 1.00 Ref. 0.85 (0.67–1.08) 1.00 Ref. 0.80 (0.55–1.15)
A/Ge 0.71 (0.27–1.87) 0.25 (0.02–2.74) 0.60 (0.17–2.06) 0.56 (0.05–6.01) 0.60 (0.11–3.25) —f —
Pinteraction = 0.39 Pinteraction = 0.95 Pinteraction = 0.32
rs230490 (G>A 5′ outside UTR)
G/G 1.00 Ref. 0.61 (0.44–0.84) 1.00 Ref. 0.69 (0.46–1.04) 1.00 Ref. 0.42 (0.22–0.82)
G/A 0.92 (0.73–1.15) 0.84 (0.62–1.13) 0.99 (0.74–1.33) 0.85 (0.58–1.24) 0.79 (0.55–1.15) 0.70 (0.40–1.23)
A/A 0.93 (0.67–1.28) 1.29 (0.82–2.03) 1.14 (0.76–1.73) 1.38 (0.78–2.44) 0.63 (0.35–1.14) 1.21 (0.52–2.82)
Pinteraction = 0.008**
,c Pinteraction = 0.26 Pinteraction = 0.02*
rs997476 (C>A 3′ outside UTR)
C/C 1.00 Ref. 0.80 (0.65–0.98) 1.00 Ref. 0.81 (0.62–1.04) 1.00 Ref. 0.67 (0.45–1.01)
C/A or A/Ad 1.08 (0.77–1.5) 1.57 (0.99–2.48) 0.82 (0.53–1.25) 1.09 (0.60–2.00) 1.58 (0.88–2.84) 2.38 (1.10–5.18)
Pinteraction = 0.03* Pinteraction = 0.16 Pinteraction = 0.08
aLimited to SNPs with a significant interaction P (<0.05) or noteworthy by FDR.
bAdjusted for age, sex, BMI, pack-years and physical activity.
cNoteworthy at 25% FDR level.
dDominant model, cases <5.
eNo individuals with the G/G genotype.
fNo cases and one control with A/G genotype.
*P ≤ 0.05, **P ≤ 0.01.
B.L.Seufert et al.
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among carriers of the variant allele who were current NSAID users 
(OR = 1.57, 95% CI 0.99–2.48) (Pinteraction = 0.03).
Replication of previous findings
Table IV compares the findings of this study with the previous study 
by Curtin et al. of genetic variability in IκBKβ and NFκB1 and the 
risk of colon and rectal cancer (9). Curtin et al. identified three indi-
vidual genotypes and one composite genotype of IκBKβ and NFκB1 
that were each inversely associated with colon cancer risk. We also 
observed trends toward a lower risk of colon cancer for the same 
genotypes. The >30% reduction in risk associated with homozygous 
carriers of NFκB1’s rs4648110 variant allele (T>A intron 22)  was 
nearly identical between the two studies under both the additive and 
recessive models of inheritance (recessive model: ORCurtin  =  0.66, 
95% CI 0.45–0.96 versus ORCFR  =  0.65, 95% CI 0.37–1.13). The 
composite genotype composed of IκBKβ’s rs3747811 (T>A intron 
1)  and NFκB1’s rs4648110 was also associated with nearly identi-
cal lower risk estimates (ORCurtin = 0.54, 95% CI 0.34–0.87 versus 
ORCFR = 0.56, 95% CI 0.28–1.12).
Curtin et  al. also identified four individual genotypes of NFκB1 
and one composite genotype of IκBKβ and NFκB1 that were associ-
ated with rectal cancer risk. Carriage of the rs13117745 (G>A intron 
5) variant resulted in a trend toward higher rectal cancer risk in both 
studies under the additive model (ORCurtin = 1.69, 95% CI 0.93–3.07 
versus ORCFR = 1.22, 95% CI 0.65–2.26). The risk estimates for the 
remaining SNPs were not replicated.
Discussion
We identified three SNPs in IκBKβ that were statistically significantly 
associated with lower colorectal or colon cancer risk. In addition, we 
report similar trends in risk estimates for many of the IκBKβ and 
NFκB1 SNPs identified by Curtin et al. (9). These findings contrib-
ute to the evidence that variation in IκBKβ and NFκB1 is associated 
with CRC risk. The activation of NFκB is a key survival mechanism 
of premalignant cells because it can block apoptosis by regulating 
anti-apoptosis proteins (36) and inhibit accumulation of reactive oxy-
gen species (37). Furthermore, the NFκB transcription factor induces 
expression of cytokines and chemokines, which help sustain an 
inflammatory state known to contribute to colorectal carcinogenesis 
(1,5,38). Although the functions of many of the tagSNPs identified 
here are not established, if these polymorphisms directly or indirectly 
modify the activation of this key transcription factor, this may explain 
their observed associations with CRC risk.
Evidence from this study and previous studies suggests that variants 
in IκBKβ are associated with a lower risk of CRC, particularly colon 
cancer. All statistically significant or noteworthy genetic variation 
in IκBKβ identified here and by Curtin et  al. trended toward a 
lower risk of colon cancer (9). The two intronic tagSNPs that had 
statistically significant associations with lower colon cancer risk in 
this study, rs5029748 and rs10958713, have no known functional 
impact, but have been previously associated with risk of colorectal 
neoplasia (9,39): in a case–control study of metachronous colorectal 
adenoma risk, rs10958713 was independently associated with a 36% 
(95% CI 13–54%) lower risk (39) and carriers of the rs5029748 
variant allele who also carried polymorphisms in NFκB1 and IL6 
had an 80% (95% CI 33–94%) lower risk of colon cancer (9). It 
seems plausible that variation in IκBKβ could negatively affect 
the function or expression of the cognate protein, IKKβ, thereby 
impairing NFκB activation and the resulting inflammation. Reduced 
levels of inflammation reduce risk of CRC (1,2) and this particular 
mechanism may have a stronger impact on colon than rectal cancer. 
A similar mechanism may also operate with regard to survival, as 
genetic variation in IκBKβ has also been associated with increased 
CRC survival among CCFR cases (11).
Contrary to previous studies (9,10) we did not observe statistically 
significant associations between NFκB1 SNPs and CRC risk. The 
non-synonymous SNP, M507V, was associated with a 40% reduced 
risk in heterozygous individuals, but this was not statistically sig-
nificant (M507V has no demonstrated functional impact and is pre-
dicted to be functionally tolerable by SIFT (Sorting Tolerant From 
Intolerant) software (40)). In the Curtin et al. study, individual SNPs 
in NFκB1 were mainly associated with the risk of rectal cancer; the 
only SNP associated with both colon and rectal cancer risk modified 
the risks in opposing directions (9). The associations in this study may 
not have reached statistical significance because family based study 
designs have lower power to identify main effects (41) and because 
of the limited number of rectal cancer cases in our study population. 
Table IV. Comparison between OR for IκBKβ and NFκB1 genotypes and composite genotypes identified by Curtin et al. (9). and results from the CCFR 
population
Cancer site Gene(s) SNP(s) Comparison(s) Model(s) Curtin et al. (9) CCFR
ORd 95% CI ORe 95% CI
Colon IκBKβ rs2272733 TT versus CC Additivef 0.56 (0.34–0.93) 0.90 (0.54–1.52)
NFκB1 rs4648110 AA versus TT Additive 0.65 (0.44–0.94) 0.68 (0.45–1.04)
AA versus TT/TA Recessive 0.66 (0.45–0.96) 0.65 (0.37–1.13)
NFκB1 rs13117745 TT versus CC Additive 0.61 (0.37–1.00) 0.80 (0.50–1.28)
TT versus CC/CT Recessive 0.64 (0.39–1.04) 0.89 (0.45–1.76)
IκBKβ/NFκB1 rs3747811/rs4648110 (TT / TT) versus  
(TA or AA / AA)
Dominant/recessive 0.54 (0.34–0.87) 0.56 (0.28–1.12)
Rectal NFκB1 rs230510a TT versus AA Additive 0.65 (0.49–0.87) 1.13 (0.73–1.79)
TT versus AA/AT Dominant 0.79 (0.51–0.94) 1.17 (0.84–1.63)
NFκB1 rs3821958b or rs230521 GG versus AA Additive 1.32 (1.00–1.75) 0.80 (0.50–1.29)
NFκB1 rs11722146c or  
rs12509517
GA/AA versus GG Dominant 1.24 (1.03–1.51) 0.99 (0.71–1.37)
NFκB1 rs13117745 TT versus CC Additive 1.69 (0.93–3.07) 1.22 (0.65–2.26)
IκBKβ/NFκB1 rs3747811/(rs11722146c  
or rs12509517)
(TT/CC) versus  
(TA or AA/CG or GG)
Dominant/dominant 1.11 (0.83–1.50) 1.02 (0.63–1.65)
Odds ratios are for the specified comparison and model of inheritance.
aThe MAF of rs230510 is close to 50% and the polymorphism results in a complementary base change (A to T), therefore it is possible the studies are 
investigating opposing associations.
brs3821958 was not genotyped in CCFR, rs3821958 and rs230521 have a LD r2 of 0.966 and the same MAF according to the Genome Variation Server.
crs11722146 was not genotyped in CCFR, rs11722146 and rs12509517 have a LD r2 of 1.000 and the same MAF according to the Genome Variation Server.
dAdjusted for age, sex, center and race.
eRestricted to Caucasians and adjusted for age and sex.
fThe OR is two times the â from the log-additive model.
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Additionally, if variation in NFκB1 modifies the risk of colon and 
rectal cancer in opposing directions, the associations could have coun-
terbalanced each other in analyses of CRC.
This study replicated several of the colon and rectal cancer risk 
estimates associated with variation in NFκB1 and IκBKβ identified 
by Curtin et al. (9). In both studies, rs4648110 of NFκB1 was associ-
ated with a ~35% decreased risk of colon cancer on its own and, when 
combined with rs3747811 of IκBKβ, a ~45% decreased risk. Using 
the UCSC Genome Browser (http://genome.ucsc.edu/), we found that 
rs4648110 is located in a potential enhancer site (42). Another NFκB1 
SNP, rs13117745, which is in moderately high LD with rs4648110 
(r2 = 0.71), also had replicated trends across the two studies; carriers 
of the variant allele had similar lower colon cancer risk and higher 
rectal cancer risk in the two studies. Opposing risk effects for colon 
and rectal cancer were also observed with rs10489113 of NFκB1 in 
this study. NFκB1 is not the first gene to be identified to have oppo-
site associations with colon and rectal cancer (43–45). Colon and rec-
tal cancers probably have distinct (as well as overlapping) etiologies 
(46,47) and these findings suggest that NFκB, and the inflammation 
that results from its activation, may impact colon and rectal cancer 
carcinogenesis differently.
The findings here are a preliminary step toward a pharmacog-
enomic approach to NSAID use. Although NSAID use is known to 
decrease risk of CRC, NSAID use brings potentially serious gastro-
intestinal toxicity and bleeding (3,14,15,48). Therefore, it would be 
valuable to identify individuals with altered benefit from NSAID use 
to ensure that any potential harm is well outweighed by the benefits. 
In this regard, polymorphisms such as rs6474387 and rs11986055 in 
IκBKβ may be of particular importance because they interact with 
NSAIDs such that carriers of the minor allele have a statistically sig-
nificantly lower risk of colon cancer, whereas carriers of the wild-type 
allele did not have decreased risk with NSAID use. We also observed 
a very strong pharmacogenetic interaction for NFκB1 rs230940 
(P = 0.008). This SNP definitely should be followed up in other stud-
ies. Recent findings have indicated that non-aspirin NSAIDs may be 
less protective than aspirin itself against rectal cancer (49); therefore, 
individuals with genotypes known only to only increase rectal cancer 
risk should not be prescribed non-aspirin NSAIDs as preventative 
treatment.
Most studies point to the inhibition of the cyclooxygenases 
(COX-1 and COX-2) in the prostaglandin synthesis pathway as the 
main mechanism by which NSAIDs reduce inflammation and risk 
of CRC (3,15,50). However, current research also points to inhibi-
tion of the NFκB-signaling pathway as a mechanism through which 
NSAIDs may reduce CRC risk by reducing inflammation and pro-
motion of apoptosis (18–20). Indeed, we observed statistically sig-
nificant interactions between genetic variation in IκBKβ and NFκB1 
and NSAID use, which is further evidence of a link between NSAIDs 
and the NFκB-signaling pathway. There are indications that some 
NSAIDs, including aspirin, directly impact the function of IKKβ in 
vitro (the protein encoded by IκBKβ) by competitively interfering 
with ATP binding (17). It is possible that variation in IκBKβ could 
affect the binding of NSAIDs to IKKβ, providing an explanation for 
the interaction between variation in IκBKβ and NSAID use. The fact 
that variation in both IκBKβ and NFκB1 interacted with NSAID 
use to modify CRC risk serves as further evidence for including the 
NFκB-signaling pathway in future studies of the chemopreventive 
effects of NSAIDs.
There are several strengths to this study. We were able to replicate 
many of the results reported by Curtin et al. (9). The large sample size 
in this study made it possible to examine colon and rectal cancer sepa-
rately; given the potential differences in etiology, it is important for 
studies to be able to make distinctions between the tumor sites. The 
case–unaffected sibling control study design also helps avoid false 
positives that can result from population stratification, and increases 
the power to detect gene–NSAID interactions (51). There are several 
weaknesses to this study as well. Associations with rare variants that 
were below our MAF cut-off (5%) and genetic variants that were 
not well represented in the relevant database may have been missed. 
Further, the family based study design may have reduced the power of 
the main effect analyses (41).
Identifying common genetic variants associated with CRC can help 
predict risk and contribute to our understanding of mechanisms of 
colorectal carcinogenesis. Additionally, examining pharmacogenetic 
interactions between common genetic variants and NSAID use may 
allow for more targeted recommendations of NSAIDs as chemopre-
ventive agents. Ultimately, our findings, which partially replicated the 
results of a previous study, suggest that variants in IκBKβ and NFκB1 
are probably associated with CRC risk. Genetic variants in IκBKβ 
appear to alter the risk of colon cancer, whereas variants in NFκB1 
appear to result in risk modifications in opposite directions for colon 
and rectal cancer. The present results also begins to shed light on links 
between variation in key NFκB-signaling pathway genes and NSAID 
use, suggesting that the prostaglandin synthesis pathway is not the 
only pathway that should be considered when investigating NSAID 
effects on CRC risk. The common variants identified here should be 
considered for future research, not only in epidemiologic studies of 
CRC, but also in functional studies of these genes.
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Supplementary Tables 1–3 can be found at http://carcin.oxfordjour-
nals.org/
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